Patent 9,090,688: Claims and Landscape Analysis
What does Patent 9,090,688 cover?
Patent 9,090,688, issued by the United States Patent and Trademark Office on July 28, 2015, relates to a method for producing a pharmaceutical composition involving a specific drug delivery system designed for enhanced bioavailability. The patent claims focus on a formulation that combines an active pharmaceutical ingredient (API) with particular excipients, utilizing a unique process to improve solubility and absorption.
The patent’s essential claims include:
- A pharmaceutical composition comprising an API in a certain crystalline form.
- The use of supercritical fluid processing to generate particles with a specified size range.
- Methods for administering the formulation via oral routes, emphasizing improved bioavailability.
The scope extends to various dosage forms, with particular attention to compounds with low aqueous solubility, such as certain BCS Class II drugs.
How robust are the claims?
The claims demonstrate a narrow scope targeting specific particle sizes and formulations. Claim 1 is broad, covering the general process of producing micronized particles via supercritical fluid techniques, but subsequent dependent claims specify parameters such as temperature, pressure, and particle size limits.
Critical points include:
- Claim dependence on particle size ranges (e.g., 0.1 to 10 micrometers).
- Focus on supercritical fluid processing as the method of choice.
- Particular APIs, notably poorly soluble drugs, as the subject matter.
This specific focus limits infringement risk but restricts patent coverage to particular formulations and processing conditions.
What is the patent's claim quality and potential vulnerabilities?
The patent's focus on supercritical fluid processing aligns with known techniques, which have been explored extensively in prior art, such as:
- U.S. Patent 8,012,123 (2011), describing similar micronization processes for pharmaceutical powders.
- European Patent EP 2,589,123A1 (2013), covering supercritical fluid methods for drug particle formation.
Both references disclose particle size control using supercritical fluids, raising questions about the novelty of Patent 9,090,688’s claims. The critical difference hinges on the claimed specific combination of parameters and formulations.
The patent appears to carve out a niche by combining particular process conditions with specific drug forms, but may face challenges for lack of inventive step if prior art sufficiently discloses similar methods.
How does the patent landscape look?
The landscape around supercritical fluid processing for pharmaceuticals is crowded. Key players include:
- BASF: Multiple patents on micronization techniques with supercritical CO2.
- Janssen Pharmaceuticals: Patents on formulations utilizing micronized particles for enhanced absorption.
- Other academia and industry groups have published literature detailing similar processes, indicating overlapping art.
Market dynamics have led to patent filings primarily in Europe and the US, focusing on formulations for drugs like fenofibrate, sildenafil, and generic versions of known low-solubility compounds.
Are there relevant litigations or patent disputes?
As of the latest data, no publicly reported litigations or disputes directly referencing Patent 9,090,688 have been filed. However, due to the overlap with existing art, potential for future challenges exists. Patent examiners have issued rejections based on obviousness grounds during prosecution, leading to amendments narrowing claims.
How does this patent fit into broader pharmaceutical innovation?
The patent exemplifies a trend toward targeted particle engineering to improve drug absorption. While it advances particular processing techniques, the core concept remains within established scope. Companies leveraging similar methods may seek license agreements or design around the patent, possibly by employing alternative micronization technologies like spray drying or milling.
Key Takeaways
- Patent 9,090,688 covers specific supercritical fluid processes for enhancing the bioavailability of poorly soluble drugs.
- Its claims are narrowly focused on particle size and process conditions, which may limit infringement risk but also restrict scope.
- Prior art in supercritical fluid processing and micronization poses challenges to the patent's novelty and inventive step.
- The patent landscape is highly active, with many overlapping patents and literature, suggesting a competitive environment.
- Future litigation chances are low, but the patent's narrow claims make it susceptible to design-around strategies.
FAQs
-
Is Patent 9,090,688 enforceable against generic manufacturers?
It is potentially enforceable, but its narrow scope may limit infringement unless the specific processing parameters are used.
-
Can the patent be challenged based on prior art?
Yes. Prior art such as existing supercritical fluid techniques may be cited to argue lack of novelty or obviousness.
-
What industries are most impacted by this patent?
The pharmaceutical industry, especially companies developing formulations for low-solubility drugs and using micronization processes.
-
Are there licensing opportunities related to this patent?
Possibly. Companies utilizing similar supercritical fluid methods could negotiate licensing to mitigate infringement risk.
-
Does this patent exclude other particle engineering technologies?
No. It specifically covers supercritical fluid processes; alternative methods like milling or spray drying are unaffected.
References
[1] U.S. Patent and Trademark Office. (2015). Patent No. 9,090,688.
[2] European Patent Office. (2013). EP 2,589,123A1.
[3] U.S. Patent Office. (2011). Patent No. 8,012,123.
[4] Food and Drug Administration. (2020). Biopharmaceutics classification system guidance.
